NEW YORK, March 12, 2013 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing oncology therapeutics that target both cancer stem cells (CSCs) and tumor bulk, announced today that Ivan Bergstein, M.D., Chief Executive Officer, will present at the 25th Annual Roth Conference on Wednesday, March 20th, 2013 at 8:00AM PT. The conference will take place at the Ritz-Carlton Laguna Niguel in Dana Point, California.
Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel oncology therapeutics that target both cancer stem cells (CSCs) as well as the tumor bulk. Among Stemline's drug candidates are SL-401 and SL-701, both of which have demonstrated clinical activity, including durable complete responses (CRs), and an overall survival (OS) benefit versus historical controls in Phase 1/2 studies of advanced cancer patients. For more information about Stemline Therapeutics, visit www.stemline.com.
CONTACT: Stemline Contact: Mark Jacobson Director, Corporate Development Stemline Therapeutics, Inc. 750 Lexington Avenue Sixth Floor New York, NY 10022 Tel: 646-502-2307 Email: firstname.lastname@example.orgSource:Stemline Therapeutics, Inc.